Immunotherapy against metastatic melanoma with human iPS cell-derived myeloid cell lines producing type I interferons

Cancer Immunology Research

Volumn 4, Issue 3, 2016, Pages 248-258

  Miyashita, Azusa ^a   Fukushima, Satoshi ^a   Nakahara, Satoshi ^a   Kubo, Yosuke ^a   Tokuzumi, Aki ^a   Yamashita, Junji ^a   Aoi, Jun ^a   Haruta, Miwa ^b   Senju, Satoru ^b   Nishimura, Yasuharu ^b   Jinnin, Masatoshi ^a   Ihn, Hironobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; SIALOADHESIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL INFILTRATION; CELL STRUCTURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; MACROPHAGE; MELANOMA CELL; METASTATIC MELANOMA; MOUSE; NONHUMAN; PHAGOCYTOSIS; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TUMOR XENOGRAFT; ANIMAL; BONE MARROW CELL; CANCER TRANSPLANTATION; CELL DIFFERENTIATION; IMMUNOLOGY; IMMUNOTHERAPY; INDUCED PLURIPOTENT STEM CELL; MELANOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; SECONDARY; SKIN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY; INDUCED PLURIPOTENT STEM CELLS; INTERFERON TYPE I; MACROPHAGES; MELANOMA; MICE, SCID; MYELOID CELLS; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS;

EID: 84962034279     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0096     Document Type: Article

References (26)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, HaanenJB, et al. Improved survivalwith ipilimumabinpatients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
3. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
4. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer 2008;8:299-308.
5. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
6. Senju S, Haruta M, Matsumura K, Matsunaga Y, Fukushima S, Ikeda T, et al. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther 2011;18:874-83.
7. Haruta M, Tomita Y, Yuno A, Matsumura K, Ikeda T, Takamatsu K, et al. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. Gene Ther 2013;20:504-13.
8. Koba C, Haruta M, Matsunaga Y, Matsumura K, Haga E, Sasaki Y, et al. Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-b against peritoneally disseminated cancer in xenograft models. PLoS One 2013;8:e67567.
9. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
10. Ishihara K, Hayasaka K, Yamamoto A. [Clinical effect and histopathologic observation of malignant melanoma by intratumoral administration of HuIFN-beta]. Gan No Rinsho 1983;29:603-7.
11. Kirkwood JM, Ernstoff M. Melanoma: therapeutic options with recombinant interferons. Semin Oncol 1985;12(4 Suppl 5):7-12.
12. Petrella T, Verma S, Spithoff K, Quirt I, McCready D, Group MDS. Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol (R Coll Radiol) 2012;24:413-23.
13. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern CooperativeOncologyGroup TrialEST 1684. JClin Oncol 1996;14:7-17.
14. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.
15. Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998;72:8150-7.
16. Ohnishi K, Komohara Y, Saito Y, Miyamoto Y, Watanabe M, Baba H, et al. CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. Cancer Sci 2013;104:1237-44.
17. Fujiwara Y, Takeya M, Komohara Y. A novel strategy for inducing the antitumor effects of triterpenoid compounds: blocking the protumoral functions of tumor-associated macrophages via STAT3 inhibition. Biomed Res Int 2014;2014:348539.
18. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005;142:481-9.
19. Saito Y, Ohnishi K, Miyashita A, Nakahara S, Fujiwara Y, Horlad H, et al. Prognostic significance of CD169+ lymph node sinus macrophages in patients with malignant melanoma. Cancer Immunol Res 2015;3:1356-63.
20. Haga E, Endo Y, Haruta M, Koba C, Matsumura K, Takamatsu K, et al. Therapy of peritoneally disseminated colon cancer by TAP-deficient embryonic stem cell-derived macrophages in allogeneic recipients. J Immunol 2014;193:2024-33.
21. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717-27.
22. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008;18:349-55.
23. SolinasG, GermanoG, MantovaniA, AllavenaP. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009;86:1065-73.
24. Barral P, Polzella P, Bruckbauer A, van Rooijen N, Besra GS, Cerundolo V, et al. CD169 (+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 2010;11:303-12.
25. Martinez-Pomares L, Gordon S. CD169+ macrophages at the crossroads of antigen presentation. Trends Immunol 2012;33:66-70.
26. Adam Z, Vorlícek J. [Therapeutic use of interferon beta]. Vnitr Lek 1994;40:329-33.